Table 1 Baseline characteristics of treatment groups*
Treatment groupContinuous budesonide (n = 58)Budesonide/placebo (n = 58)Disodium cromoglycate (n = 60)
Age (years)7.0 (5 to 10)6.7 (5 to 10)6.9 (5 to 10)
Male (%)596654
Tanner pubertal stage I/II58/158/161/2
Standing height (cm)128.4 (108 to157)125.1 (106 to 148)125.6 (105 to 148)
Standing height, standard deviation scores (SDS)0.04 (−0.32 to 0.54)0.03 (−0.30 to 0.39)0.04 (−0.43 to 0.32)
Body mass index (kg/m2)17.516.916.9
Skin prick test positive (n)354136
Duration of symptoms (months†)12.8 (1.1 to 70.5)11.3 (2.0 to 76.4)11.7 (3.0 to 70.8)
Wheeze ever (n)354233
Asthma symptom score (0–10)‡1.5 (0.0 to 5.5)1.7 (0.0 to 4.5)1.9 (0.0 to 5.7)
Rescue medication, dose/24 h‡0.47 (0 to 4.0)0.55 (0 to 3.7)0.68 (0 to 2.8)
Morning PEF rate (l/min)‡182 (78 to 301)176 (68 to 313)184 (94 to 363)
Morning PEF (% predicted value)‡76 (43 to 105)77 (42 to 112)79 (54 to 107)
FEV1 (L†)1.43(0.89 to 2.15)1.32 (0.72 to 2.36)1.37 (0.63 to 2.45)
FEV1 (%† predicted value)87 (57 to 111)82 (52 to 107)83 (57 to 107)
FVC (% predicted value)90 (64 to 112)87 (57 to124)89 (56 to 120)
  • *Values are means with range in parentheses, unless otherwise stated; †no correlation between duration of the symptoms and FEV1. ‡Data from the run-in period. FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; PEF, peak expiratory flow rate.